MRI Screening of Placenta Adhesion Abnormalities
NCT: NCT04328532 · RECRUITING
Brief Summary
Placenta Adhesion Abnormalities (PAA) are the consequence of an excessive invasion of the placenta within the myometrium. PAA are related to severe maternal pregnancy outcomes, especially in case of incidental discovery during delivery that increase the risk of intraoperative massive bleeding, hysterectomy and even maternal death. Ultrasound is the standard modality for diagnosing PAA, but Magnetic Resonance Imaging (MRI) has been increasingly performed in the case of inconclusive sonographic findings. However, standard morphological MRI sequences appear as insufficient to improve the sensitivity and specificity values for detecting PAA, while quantitative MRI may be more efficient. The main objective of this study is to characterize the diagnostic performance of quantitative MRI parameters (mainly Apparent Diffusion Coefficient, T2 and T2\*) reflecting placental perfusion and/or oxygenation at high field, without injection of gadolinium-based agent, for the detection of PAA in women with ongoing pregnancy between 30 and 38 weeks of gestation with risk factors for PPA.
Frequently Asked Questions
What is MRI Screening of Placenta Adhesion Abnormalities?
MRI Screening of Placenta Adhesion Abnormalities is a clinical trial registered under NCT04328532. Current status: RECRUITING.
What is the status of NCT04328532?
The current status of NCT04328532 (MRI Screening of Placenta Adhesion Abnormalities) is: RECRUITING.
When did MRI Screening of Placenta Adhesion Abnormalities start?
MRI Screening of Placenta Adhesion Abnormalities started on 2020-10-21.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.